A detailed history of Creative Planning transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Creative Planning holds 88,477 shares of BCRX stock, worth $626,417. This represents 0.0% of its overall portfolio holdings.

Number of Shares
88,477
Previous 86,197 2.65%
Holding current value
$626,417
Previous $772,000 13.08%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$7.55 - $9.06 $17,214 - $20,656
2,280 Added 2.65%
88,477 $671,000
Q2 2025

Aug 08, 2025

BUY
$6.41 - $11.19 $56,074 - $97,890
8,748 Added 11.3%
86,197 $772,000
Q1 2025

May 15, 2025

SELL
$7.06 - $9.39 $40,778 - $54,236
-5,776 Reduced 6.94%
77,449 $580,000
Q4 2024

Feb 14, 2025

BUY
$7.03 - $8.43 $238,162 - $285,591
33,878 Added 68.65%
83,225 $625,000
Q3 2024

Oct 11, 2024

BUY
$6.41 - $8.69 $17,524 - $23,758
2,734 Added 5.87%
49,347 $375,000
Q2 2024

Aug 15, 2024

BUY
$4.13 - $6.79 $82,657 - $135,895
20,014 Added 75.24%
46,613 $288,000
Q1 2024

May 10, 2024

BUY
$4.89 - $7.65 $63,506 - $99,350
12,987 Added 95.41%
26,599 $135,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $67,787 - $92,153
13,612 New
13,612 $81,000
Q2 2021

Aug 04, 2021

SELL
$9.5 - $17.24 $175,360 - $318,233
-18,459 Closed
0 $0
Q1 2021

Apr 30, 2021

BUY
$7.37 - $13.61 $136,042 - $251,226
18,459 New
18,459 $188,000
Q2 2018

Jul 20, 2018

SELL
$4.6 - $6.52 $84,410 - $119,641
-18,350 Closed
0 $0
Q1 2018

Apr 18, 2018

BUY
$4.35 - $5.82 $79,822 - $106,797
18,350 New
18,350 $88,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.32B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.